Tag: Pembrolizumab gastric cancer approval

Home / Pembrolizumab gastric cancer approval

Categories

Pembrolizumab with chemotherapy is approved by the USFDA for HER2-negative gastric or gastroesophageal junction adenocarcinoma

The Food and Drug Administration approved pembrolizumab (Keytruda, Merck) in combination with fluoropyrimidine- and platinum-containing chemotherapy on November 16, 2023. This approval is for the ini...
pembrolizumab-gastric-cancer-approval

Scan the code